EUDA
Milestones
2019
Launched with a mission to lead non-invasive, preventive, longevity-focused healthcare across Southeast Asia and China.
2020
A Singapore property and security management firm, to integrate property management into its ecosystem and cross-sell healthcare services.
First health-tech firm supported by Singapore’s IMDA PSG for AI-driven COVID prevention and medical testing initiatives.
2022
Completed business combination with 8i Acquisition 2 Corp., becoming a U.S.-listed public company.
2024
Brought a direct-selling wellness portfolio under EUDA, expanding distribution in Singapore and Malaysia.
Positioned the company to access growth capital and accelerate expansion across Southeast Asia.
2025
Through an authorized distributor of Guangdong Cell Biotech, began offering regenerative therapy access in Singapore & Malaysia.
Entered an at-the-market offering agreement to raise growth capital.
Added a next-generation supplement to EUDA’s wellness portfolio.
Secured additional financing through a convertible note structure.
Secured distribution of Shenzhen Inno Immune’s T-cell immunotherapies to strengthen EUDA’s advanced therapy offerings.
Entered a letter of intent for an iPSC platform; planned Shenzhen iPSC lab and collaboration track with Prof Lim Kah Meng for R&D and clinical pathways.
